Innate Pharma S.A. (IPHA) Stock Price, News & Analysis

Innate Pharma S.A. (IPHA) is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company concentrates on antibody-engineering and innovative target identification to create next-generation antibody therapeutics. Innate Pharma’s shares trade on Euronext Paris under the ticker IPH and on Nasdaq in the United States under the ticker IPHA.

According to company disclosures, Innate Pharma develops therapeutic approaches that include monoclonal antibodies (mAbs), Antibody Drug Conjugates (ADCs) and multi-specific NK cell engagers built on its proprietary ANKET® (Antibody-based NK cell Engager Therapeutics) platform. The company describes its pipeline as a portfolio of differentiated potential first- and/or best-in-class assets in areas of high unmet medical need in oncology.

Core focus and pipeline

Innate Pharma reports that it is prioritizing investment in what it considers its highest-value clinical assets: IPH4502, lacunatab, and monalizumab (the latter partnered with AstraZeneca). In its public communications, Innate Pharma also highlights additional clinical and preclinical programs emerging from the ANKET® platform and collaborations.

The company states that its pipeline includes:

• IPH4502, described as a differentiated Nectin-4 ADC in development in solid tumors.
• Lacutamab, described as a first-in-class anti-KIR3DL2 monoclonal antibody developed in advanced forms of cutaneous T cell lymphomas and peripheral T cell lymphomas. Company materials note that lacutamab has been evaluated in the Phase 2 TELLOMAK trial in cutaneous T‑cell lymphoma, with a confirmatory Phase 3 trial (TELLOMAK‑3) in preparation.
• Monalizumab, an anti‑NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer, including evaluation in the Phase 3 PACIFIC‑9 trial run by AstraZeneca.
• IPH6501, an ANKET® anti‑CD20 with IL‑2V in a Phase 1/2 trial in B‑cell non‑Hodgkin’s lymphoma.
• IPH6101, an ANKET® anti‑CD123 program for which Innate Pharma reports it has regained rights from Sanofi.
• IPH5201, an anti‑CD39 antibody developed in collaboration with AstraZeneca and evaluated in the MATISSE Phase 2 trial in neoadjuvant lung cancer.
• IPH5301, an anti‑CD73 antibody studied in the investigator‑sponsored CHANCES Phase 1 trial.
• IPH62, an NK‑cell engager program targeting B7‑H3 from the ANKET® platform, under preclinical development in collaboration with Sanofi.
• SAR’514/IPH6401, a BCMA‑targeting ANKET® program that Sanofi has decided to pursue in autoimmune indications under an existing license agreement.

Earlier descriptions of Innate Pharma’s activities also reference the ANKET® platform as a proprietary technology for antibody-based NK cell engager therapeutics and list additional historical pipeline names such as IPH4502, lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Business model and collaborations

Innate Pharma describes itself as a clinical-stage biotechnology company whose revenue results from payments received under research, collaboration and licensing agreements with pharmaceutical companies. Public information notes that collaboration and licensing revenue has been associated with agreements with partners including Sanofi and AstraZeneca.

The company states that it has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as academic and research institutions. These collaborations are described as focused on advancing innovation in immuno-oncology and accelerating research and development based on Innate Pharma’s antibody-engineering expertise and ANKET® platform.

Geographic footprint and listings

Innate Pharma reports that it is headquartered in Marseille, France, with a US office in Rockville, Maryland. The company’s ordinary shares are listed on Euronext Paris (ticker: IPH), and American Depositary Shares are listed on Nasdaq in the US (ticker: IPHA). Company communications also reference an ISIN code FR0010331421 and a legal entity identifier (LEI) 9695002Y8420ZB8HJE29 for its securities.

Regulatory and clinical-stage profile

Innate Pharma repeatedly characterizes itself as a clinical-stage biotechnology company, emphasizing that its programs are in various stages of clinical and preclinical development. The company highlights regulatory designations for lacutamab, including Fast Track designation from the US Food and Drug Administration (FDA), PRIME designation from the European Medicines Agency (EMA) for Sézary syndrome, and Orphan Drug designations in the US and EU for cutaneous T‑cell lymphoma. Company materials also state that lacutamab has received Breakthrough Therapy Designation for Sézary syndrome.

Public updates describe multiple ongoing trials, such as Phase 1 and Phase 2 studies for IPH4502, lacutamab, and ANKET® assets, as well as the AstraZeneca‑run Phase 3 PACIFIC‑9 trial for monalizumab in unresectable Stage III non‑small cell lung cancer. These disclosures underline Innate Pharma’s focus on oncology indications with high unmet medical need.

Capital markets and investor information

Innate Pharma periodically publishes regulatory news on the number of shares outstanding and voting rights, in line with French market regulations. The company also releases a financial calendar outlining planned publication dates for financial statements and revenue updates, as well as the timing of its annual general shareholders meeting. In addition, Innate Pharma holds conference calls and webcasts to discuss business updates and financial results, and participates in investor conferences and dedicated analyst and investor events.

According to company statements, Innate Pharma has used tools such as an at‑the‑market (ATM) program for potential issuance of American Depositary Shares and has received equity investments from partners, including an equity investment by Sanofi under the terms of a collaboration agreement.

Sector and industry classification

Innate Pharma S.A. operates in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector, with a specific focus on biotechnology and immuno-oncology. Its activities, as described in public disclosures, center on the research and development of antibody-based therapeutics and NK cell engager technologies for cancer treatment, rather than on large-scale commercial manufacturing.